Beyond Gadolinium: A Comparative Review of Iron Oxide Nanoparticles as Emerging MRI Contrast Agents for Personalized Medicine

Haydar Abdulkadeer Taheer Al-Shimmari[1,2], Ab Hamid Suzana[1], Subapriya Suppiah[1], Duha A. Kadhim[3], Tawfiq Yousef Tawfiq Zyoud[1] ,Weaam H. Abdullah[4]

[1]*Department of Radiology and Imaging, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia*
[2]*Department of Radiological Techniques, College of Health and Medical Techniques/Baghdad, Middle Technical University, 10047 Bab Al Muadham, Baghdad, Iraq*
[3]*Department of Physics, College of Science, Al-Mustansiriyah University, Baghdad- Iraq*
[4] *Department of Oral , College of Dintistry Medical Technical Laboratory Department, AL-Hikmah UniversityCollege, Ministry of Higher Education and Scientific Research, Baghdad, Iraq*
Email: haydar114@gmail.com suzana@upm.edu.my, subapriya@upm.edu.my, duha.abdual@uomustansiriyah.edu.iq dr.weaamhmoud@gmail.com

KEYWORDS

Gadolinium, Iron Oxide Nanoparticles, Contrast Media, MRI, Dual-Mode, Imaging, Theranostics, Synthesis, Biocompatibility

ABSTRACT

MRI is a standard diagnostic tool in compare to the other diagnosis equipment's due to its noninvasiveness and excellent soft-tissue contrast. Intrinsic tissue contrast based on proton density and relaxation times may not be enough to detect disease alterations early. Gadolinium-based contrast agents (GBCAs) have traditionally been used to improve T_1-weighted images by dramatically reducing relaxation durations. They can visualize tumors, vascular abnormalities, and inflammatory lesions, but gadolinium accumulation and the risk of nephrogenic systemic fibrosis (NSF) have led to the hunt for safer alternatives. Super paramagnetic iron oxide nanoparticles (SPIOS-NPs) characteristics make them a promising replacement. Recent improvements have resulted to ultra-small IONPs that boost T_1 contrast and enable dual-mode imaging capabilities, in addition to providing T_2 contrast by shortening relaxation durations. IO-NPs can also be functionalized with targeted ligands or therapeutic molecules for theranostics applications that integrate diagnosis and treatment, a crucial component of personalized medicine. This review provides a comprehensive comparison of GBCAs and IO-NPs, discussing their fundamental mechanisms of action, synthesis methods, clinical performance, and safety profiles. It also addresses current challenges such as nanoparticle aggregation, variability in signal intensity, and scalability in production. Future directions include the development of multifunctional, dual-mode agents and the standardization of imaging protocols. By synthesizing current knowledge and identifying areas for further research, this review provides a roadmap for the next generation of MRI contrast agents that suit the objectives of personalized diagnostic imaging by synthesizing current knowledge and identifying research gaps.

1.0 Introduction

With great soft-tissue contrast and comprehensive anatomical information without the risks related with ionizing radiation, magnetic resonance imaging (MRI) has become one of the most important diagnostic techniques in modern medicine in compare to the other imaging modalities [1-3]. MRI's fundamental idea is based on nuclear magnetic resonance: hydrogen protons mostly present in water molecules align with a strong stationary magnetic field (B_0), therefore creating a low energy equilibrium state. These protons receive energy from a radiofrequency (RF) pulse and become excited out of balance. Returning to their natural condition, they generate RF signals that receiver coils detect and translate into high-resolution images [4]. From neurological problems and musculoskeletal injuries to oncological diseases, this process makes MRI absolutely essential for evaluating a wide spectrum of clinical ailments [5]. Although the intrinsic contrast generated by variations in tissue proton density and natural relaxation periods (T_1 and T_2) is frequently insufficient for identifying early pathological alterations, despite their several benefits. Many times, minute differences in the relaxation characteristics of tissues lack sufficient contrast to precisely identify inflammatory lesions or early-stage tumors, therefore causing misdiagnoses. Exogenous contrast chemicals are given to change the relaxation behavior of water protons, so overcoming this restriction and increasing the signal variations between healthy and sick tissues and so boosting diagnosis accuracy [6]. Nanoparticles, have been investigated for their potential as MRI contrast agents, showing promising preliminary data in terms of both imaging capability and safety [7,8].

Contrast-enhanced MRI has always revolved mostly on gadolinium-based contrast agents (GBCAs). With seven unpaired electrons, the Gd^{3+} ion has a strong magnetic moment that drastically reduces T_1 relaxation times, hence increasing the brightness of images weighted in T_1-weight. When visualizing brain tumors, vascular abnormalities, and inflammatory processes, this feature has shown quite helpful [6], [9]. Still, the great clinical use of GBCAs raises serious safety issues. Studies have shown gadolinium deposition in important tissues including the brain, bones, and skin, even in patients with normal renal function [10]. And an elevated risk of nephrogenic systemic fibrosis (NSF) in those with renal impairment [11].

Given these problems, iron oxide nanoparticles (IO-NPs) have become increasingly interesting contrast agent. Unlike GBCAs, which mostly improve T_1-weighted imaging, IO-NPs have special superparamagnetic properties that mostly shorten T_2 relaxation durations, so rendering tissues seeming darker on T_2-weighted scans [12], as shown in figure 1. Ultra-small IONPs developed from recent breakthroughs in nanotechnology can also lower T_1 relaxation periods, hence offering dual-mode imaging capabilities [13]. Furthermore, IO-NPs have improved biocompatibility; since iron is a vital component of the human body, agents formulated with biocompatible coatings like polyethylene glycol (PEG) show less toxicity and less long-term accumulation than gadolinium-based agents [14] ,[15].



Figure 1: GBCAs: (Panel A T1-positive contrast agents that shorten the T1 relaxation time, making afflicted tissues brighter on T1-weighted MRI images) (SPION) (Panel A), T2-negative contrast agents that shorten T2 relaxation time, darkening tissues on T2-weighted MRI images [12].

Additionally, the surface of IO-NPs can be readily changed to attach therapeutic molecules or targeting ligands, thereby enabling theranostic uses combining diagnosis imaging with targeted therapy [16], [17]. Demand for safe, efficient, and flexible contrast agents keeps ever-growing as MRI technology develops with improvements in pulse sequence design, higher magnetic field strengths, and multimodal imaging integration. By means of their mechanisms, clinical performance, safety profiles, and future possibilities in the era of personalized medicine, this paper offers a thorough comparison of GBCAs and IO-NPs. Therefore, the primary aim of this review is to provide a comprehensive comparison between gadolinium-based contrast agents (GBCAs) and iron oxide nanoparticles (IONPs) by examining their historical evaluation, fundamental mechanisms, clinical performance, and safety profiles. Additionally, we aim to highlight ongoing challenges in manufacturing, imaging protocol standardization, and translational research, ultimately guiding the development of next-generation MRI contrast agents that align with the principles of personalized medicine.

2.0 Fundamentals of MRI and Contrast Mechanisms

MRI is a non-invasive diagnostic method that uses the magnetic characteristics of nuclei—mostly hydrogen protons in water molecules—to produce high-resolution anatomical images, therefore obtaining comprehensive images of the human body. Bernstein, King, and Zhou (2004) and Hashemi, Bradley, and Lisanti (2017) claim that a patient placed in a strong static magnetic field (B_0) will align the hydrogen protons with the field, therefore creating a low-energy equilibrium condition, as show in figure 2. These protons receive energy from a radiofrequency (RF) pulse and are stimulated away from equilibrium. They produce RF signals when they relax

back to their natural condition that are picked up by receiver coils and then transformed into finely detailed images.

Two relaxation processes define the image contrast in MRI most of the time. After excitation, protons must realign with the magnetic field; this is known as T_1 (longitudinal) relaxation; shorter T_1 periods produce higher signal intensity on T_1-weighted pictures. Darker signals on T_2-weighted images arise from the process by which the coherent transverse magnetization decays owing to interactions with protons and local magnetic field inhomogeneities [4][5].

By changing these relaxation times, contrast agents help to raise image quality even more. GBCAs are especially effective, claims Caravan et al. (1999), since the Gd^{3+} ion—with its seven unpaired electrons—significantly reduce T_1 relaxation periods. On T_1-weighted scans, this produces brilliant, improved pictures that help to visualise tumours, vascular abnormalities, and inflammatory diseases.

SIONPs on the other hand mostly produce local magnetic field inhomogeneities that shorten T_2 relaxation durations, resulting in darker areas on T_2-weighted images. Ultra-small SPIO-NPs that can also lower T_1 relaxation periods have been made possible by recent developments, hence offering dual-mode imaging potential [12] [18].

Further raising MRI's sensitivity to these relaxation changes are developments in pulse sequence design and higher magnetic field strengths, therefore highlighting the crucial part contrast agents play in improving diagnostic accuracy.



Figure 2: illustrates the mechanisms of T1 and T2 relaxation in magnetic resonance imaging, demonstrating how contrast agents enhance diagnostic image quality [1].

Further raising MRI's sensitivity to these relaxation changes are developments in pulse sequence design and greater magnetic field strengths. Tailored to highlight the particular relaxation variations between tissues, pulse sequences such as inversion recovery and multi-echo techniques help to improve diagnostic accuracy [19]. Furthermore, important for assessing the effectiveness of these agents is the quantitative characteristic known as relativity, which is defined as the change

in relaxation rate per unit concentration of the contrast agent. These principles together enable the functioning of IONPs and GBCAs, therefore fostering ongoing innovation in individualized diagnostic imaging.

3.0 Gadolinium-Based Contrast Agents (GBCAs)

3.1 Historical Evolution and Clinical Applications

Introduced in the early 1980s, GBCAs such as gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) revolutionized MRI by providing dramatic T_1 shortening, resulting in bright images that improved the detection of tumors, vascular abnormalities, and inflammatory lesions [1].[6]. Over time, two major classes emerged linear and macrocyclic agents. Macrocyclic GBCAs offer greater kinetic stability and are less prone to releasing free gadolinium ions, a key factor in minimizing adverse effects [20] [21]. The timeline of gadolinium-based contrast agent development, highlighting major milestones, challenges, and recommendations from key studies, as shown in Table.

Table 1: Timeline of Gadolinium-Based Contrast Agent development

Year	Outcome	Challenges	Recommendations
1981	First proposal of gadolinium as an MRI contrast agent	Toxicity of free gadolinium requiring chelation	Development of safe chelating agents
1984	Clinical testing of Gd-DTPA	Need for comprehensive safety studies	Expanded clinical trials
1988	FDA approval of Magnevist (Gd-DTPA)	Concerns about potential side effects	Long-term monitoring of adverse effects
1992	Development of macrocyclic agents	Higher costs compared to linear agents	Improve manufacturing processes to reduce cost
2006	Discovery of the link between GBCAs and NSF	Severe risk for patients with renal failure	Develop screening protocols for high-risk patients
2014	Discovery of gadolinium deposition in brain tissues	Concerns over long-term effects	Conduct long-term follow-up studies
2017	EMA restrictions on linear agents	Need for safer alternatives	Develop gadolinium-free contrast agents
2023	Development of new gadolinium-free contrast agents	Challenges matching the efficacy of gadolinium	Continue research into safer alternatives

3.2 Mechanism of Action and Image Enhancement

The relaxation properties of water protons are key to GBCAs' diagnostic efficacy. GBCAs readily enter vascular and interstitial regions after intravenous administration. Gadolinium ions chelated by ligands interact directly with water molecules in their inner coordination sphere. Dipolar interactions boost T_1 relaxation rate, reducing relaxation time and increasing signal intensity on T_1-weighted images [6].



Figure 3: Effect of contrast agent on T1-weighted images. Left image without, right image with contrast medium administration

Relaxivity (r_1), the change in relaxation rate per unit concentration of the agent, measures the efficiency of a GBCA. Relaxivity is affected by the quantity of water molecules directly coordinated to the gadolinium ion (q), their residence time (τ_M), and the complex's rotational correlation time (τ_R) [19]. A high q value and ideal τ_M maximise the paramagnetic effect for water molecules, while a solid molecular structure improves relaxivity by decreasing rapid tumbling [9].

Although T_1-weighted imaging is the main diagnostic use of GBCAs, they can also affect T_2 relaxation to a lesser amount. Their design prioritises T_1 contrast enhancement. Advanced chemical design has produced macrocyclic GBCAs with good relaxivity and kinetic stability, minimising gadolinium dissociation and tissue deposition [21]. Figure 4 shows the optimizing GBCA efficiency in MRI and enhancing GBCA diagnostic efficiency in current study.



Figure 4: shows the optimizing GBCA efficiency in MRI and enhancing GBCA diagnostic efficiency.

3.3 Safety Concerns and Limitations

Despite their diagnostic advantages, GBCAs are associated with notable safety issues:

- **Nephrogenic Systemic Fibrosis (NSF):** GBCAs clearly provide diagnostic benefits, but their safety profile has grown to cause great worry. Numerous investigations have recorded gadolinium deposition in many organs, including the brain, even in patients with normal renal function [21]. These results have attracted more attention from regulatory authorities and caused a review of GBCA use, especially in susceptible groups including pediatric patients and those with renal insufficiency [11], shown in Table 2.
- **Gadolinium Retention:** Among the most serious side effects associated with GBCA treatment is nebrogenic systemic fibrosis (NSF). Mostly seen in patients with pre-existing renal failure, NSF is marked by significant fibrosis of the skin and internal organs. While more stable macrocyclic drugs have helped to lower the prevalence of NSF, the risk still causes great worry [22]. Furthermore, not entirely known are the long-term effects of gadolinium accumulation, including possible neurotoxicity, which calls more research.

Image	Description	Reference
 Gadolinium Retention in Brain Tissue	This image compares gadolinium retention in brain tissue by linear agent gadobenate dimeglumine with macrocyclic agent gadoteridol. Gadolinium retention in the brain was substantially higher for linear agents.	Kobayashi, (2021). 22
 Skin nephrogenic fibrosing dermopathy.	Exhaustion. Hard, bound-down extremity skin. Follicular dimpling (peau d'orange) is common. Elsevier has granted permission to reproduce the image ©2010 by the American Academy of Dermatology from Girardi et al12.	Rudnick, M. R., (2021) 23
 Gadolinium Accumulation in Bone	Gadolinium buildup in bone tissue raises concerns about long-term retention and toxicity.	Turyanskaya, (2020) 24
 Gadolinium Retention Comparison	Liver and kidney Gd concentrations were detectable one month following GBCA. Kidney and liver ranges were 39–294 and 0.36–1.22 nmol Gd/g tissue, respectively.	van der Molen, (2024) 25

- **Cost and Monitoring:** The restrictions linked with GBCAs go beyond only safety issues. Some therapeutic environments may find these agents difficult to get and practically useful given their very high cost and demand for thorough safety monitoring. Furthermore, even if macrocyclic medicines show better stability, pharmacokinetics and biodistribution vary among different formulations, which can influence diagnosis consistency [5] [15]. as shown in figure 5.



Figure 5: Safety Concerns and Limitations of GBCA.

4.0 Iron Oxide Nanoparticles based contrast agent

4.1 Historical Overview

Iron oxide nanoparticles (IONPs) have been studied as MRI contrast agents for several decades, originating from early formulations of superparamagnetic iron oxide (SPIO) and ultrasmall superparamagnetic iron oxide (USPIO) released in the 1990s. Examples comprise Feridex I.V. (authorised for hepatic imaging), Resovist, AMI-227 (commercialised as Combidex® or Sinerem®), NC100150 (Clariscan®), and VSOP C184 [18] [26].These drugs were largely employed to augment T_2-weighted imaging by producing local magnetic field inhomogeneities, resulting in darker signals in tissues such as the liver, spleen, or metastatic lymph nodes.

Despite the superior sensitivity of numerous early SPIO/USPIO products in identifying focal lesions, several were ultimately discontinued or faced restricted clinical availability owing to economic considerations and the introduction of novel agents[26]. These innovative formulations established the foundation for contemporary ultra-small iron oxide nanoparticles, which offer T_2 contrast and can be modified to reduce T_1 relaxation durations, facilitating dual-mode imaging[12][13]. Furthermore, advancements in nanoparticle synthesis techniques such as co-precipitation, thermal breakdown, and solvothermal methods have significantly enhanced the regulation of size, shape, and surface chemistry, hence improving biocompatibility and relaxivity profiles [15] [27].

Currently, IONPs are advancing through extensive research on multifunctional coatings, targeted ligands, and theranostic functionalities. Utilising extensive preclinical and clinical expertise, these novel iron oxide-based agents seek to mitigate the safety issues and diagnostic constraints associated with conventional gadolinium-based contrast agents, facilitating the advancement of more sophisticated, personalised MRI diagnostics.

4.2 Clinical and Preclinical Evaluations

Preclinical studies have shown that IONPs improve contrast in both T_1- and T_2-weighted images in animal models, particularly for liver and lymph node imaging (Bulte & Kraitchman, 2004; Deoni et al., 2008). Clinically, agents such as ferumoxytol have been used for MRI contrast enhancement and for therapeutic purposes. However, challenges remain in standardizing large-scale production and imaging protocols, as well as addressing issues related to signal intensity and long-term retention in certain tissues [15] [28].



Figure 6: images MRI diagnostic of GBCA and IO-NPs in vitro and vivo.

4.2.1 In vitro

In vitro measurements of IONP size, shape, surface chemistry, and cellular absorption can help explain their cell interactions. Targeted treatments benefit from positively charged nanoparticles (10–50 nm)'s better cellular internalization [29]. Singh et al. (2010) indicated ROS production and the necessity to monitor cytotoxicity early in development. Ultrasonic computed tomography and quantitative ultrashort echo time MRI track IONPs in regenerative medicine in vitro [30-32]. In vitro research is less sophisticated than in vivo, limiting clinical prognostic value.

4.2.2 In Phantoms

Phantom studies evaluate signal intensity, relaxivity, and contrast enhancement in a controlled setting. Agar-based phantoms improve size and concentration-dependent MRI contrast [33]. These studies are needed to standardise imaging before in vivo trials.

Phantom studies don't account for biological complexity and experimental protocol variation, hence complementing in vivo models are needed to predict nanoparticle behaviour [34].

4.2.3 In Vivo

In vivo biodistribution, safety, and treatment efficacy are investigated, bridging lab and clinical studies. Ferumoxytol-enhanced MRI can imaging lymph nodes, and Sun et al. (2016) found IONP buildup in brain tumours, demonstrating their diagnostic potential. Recent IONP dual-modality imaging combines photoacoustic and MRI [33] [35]. Radionuclide treatment IONPs have been assessed using voxel-based dosimetry [36]. Due to interspecies physiological differences, high costs, and ethics, clinical translation requires more standardized models.

4.2.4 In Clinical application

IO-NPs can substitute GBCAs in nephrogenic systemic fibrosis patients. Many studies have proved their usefulness in T2-weighted MRI, especially liver and spleen imaging. Ferumoxytol, an FDA-approved IO-NP, detects hepatic lesions better than GBCAs [37]. Furthermore, long-term safety, variable imaging results, and limited therapeutic uses need further study. IONPs are being studied as theranostics agents that combine imaging and targeted drug delivery. In animal models, functionalized IO-NPs with tumor-specific antibodies delivered chemotherapeutic medicines to tumors, improving efficacy and lowering systemic toxicity [38]. Ferumoxytol, originally licensed for iron-deficient anaemia, now images vascular inflammation and tumors. Immune system interactions and long-term biocompatibility must be addressed before clinical use [39]. IO-NPs have potential, but further study is needed to standardize clinical methods, validate biocompatibility, and scale production. Addressing these concerns would hasten their safe and effective introduction into routine diagnostic and therapeutic usage, as shown in figure 7.



Figure 7: the evolution of IO-NPs in medical application.

4.3 Mechanisms of actions and Unique Properties

An alternative to GBCAs that is transformative is represented by IO-NPs. Due to the fact that they are superparamagnetic; they are able to produce local magnetic field inhomogeneities, which in turn allow them to cause considerable T_2 shortening. The development of ultra-small IONPs (with a size of less than 10 nanometres) has been made possible by advancements in nanoparticle synthesis. These IONPs have the ability to shorten T_1 relaxation periods, hence providing dual-mode imaging capabilities [13] [14]. It is possible to optimize the relaxivity qualities of IONPs by using advanced synthesis techniques such as co-precipitation, solvothermal methods, thermal decomposition, and microemulsion. These approaches allow for exact control of the size, shape, and surface properties of IONPs. Surface modifications, such as PEGylation, improve biocompatibility and minimise aggregation [22] [40]. For example, non-spherical IO-NPs may display higher relativity due to magnetic anisotropy. Surface changes also improve biocompatibility.

4.4 Biocompatibility and Safety Profile

IO-NPs biocompatibility is a major advantage over gadolinium-based contrast agents. Human physiology requires iron, and the body has well-established iron metabolism and elimination processes. IONPs with biocompatible coatings have low cytotoxicity and few side affects in vivo[14]. Unlike GBCAs, which can cause long-term deposition and toxicity, IONPs are metabolized into iron ions that can be stored in ferrite complexes or hemoglobin.

Surface changes are critical to IONP biocompatibility, according to research. PEG coatings prevent plasma protein aggregation and opsonisation and extend circulation by evading reticuloendothelial system (RES) clearance [14]. Repeated imaging studies require stealth to minimize immune reactions and avoid fast clearance for high-quality, consistent images.

In addition to their low toxicity, IONPs reduce tissue retention risk. Although gadolinium buildup in the brain and other tissues is a safety concern, iron oxide nanoparticles are removed by the body's metabolic mechanisms. IONPs' biodegradable coatings help the liver and spleen clear them, lowering the risk of buildup in sensitive tissues [41-42]. Furthermore, preclinical investigations show that IONPs have little cytotoxic effects on many cell types. MTT and live/dead staining have indicated that IONPs do not harm cellular viability at therapeutically relevant concentrations [12]. Animal studies have shown that IONP formulations are well tolerated after several doses. IONPs are appealing for paediatric imaging and renal dysfunction patients due to their better safety profile [15]. Gadolinium-based agents pose considerable hazards.

IO-NPs continue to show promise, but establishing consistent safety across formulations is difficult. Synthesis processes, particle size distributions, and surface fictionalization affect IONPs in vivo. Thus, standardizing production techniques and extensive preclinical evaluation are essential for widespread clinical application of these nanoparticles [12] [16] . Finally, IONPs' biocompatibility and safety make them better than gadolinium-based contrast agents. Their low cytotoxicity, fast biodegradation, and natural clearance pathways prevent long-term side effects, making them ideal for susceptible patients. IONPs may be a safer, more effective MRI contrast enhancement option as nanoparticle manufacturing and surface engineering improve.

5. Comparative Analysis: GBCAs versus IONPs

A side-by-side comparison highlights key differences between the two classes:

This comparative table demonstrates that while GBCAs have a well-established clinical track record, IO-NPs (Ferumoxytol) as example offer significant advantages in terms of safety and multifunctionality, with the potential to be tailored for targeted and theranostics applications.

Comparison Point	IO-NPs (Ferumoxytol)	Gadolinium	References
Safety	Generally safe and well-tolerated in clinical settings	Risk of nephrogenic systemic fibrosis (NSF), especially in patients with kidney failure	Arami et al., 2015; Schieda et al., 2018 13 42
Efficacy	Provides good contrast enhancement in T1- and T2-weighted MRI	Excellent contrast in T1-weighted MRI	Jeon et al., 2021; Gulani et al., 2017 10 -43
Targeting	Can be functionalized to target specific cells or tissues	No targeted capabilities	Gupta et al., 2005; Caravan et al., 1999 36 6
Multifunctionality	Combines imaging, drug delivery, and hyperthermia therapy	Primarily used for contrast imaging only	Shubayev et al., 2009; Wahsner et al., 2018 16 44
Cost	Generally less expensive	More expensive	Ajinkya et al., 2020; Runge & Heverhagen, 2022 15 45
Availability	Widely available in various forms	Limited availability due to higher cost	Farinha et al., 2021; Daldrup-Link, 2017 26 46
Overall Safety and Efficacy	Well-tolerated and effective for multiple uses	Effective contrast agent but carries NSF risk	Laurent et al., 2008; Kanda et al., 2014 47 11
Biocompatibility	Well-tolerated; minimal deposition in tissues	Retention in brain and other tissues with long-term effects	Radbruch et al., 2015; Arami et al., 2015 48 13
Excretion	Naturally excreted; low retention	Can persist in the body for years	Arami et al., 2015; Kanda et al., 2014 13 11
Magnetic Properties	Superparamagnetic, enabling manipulation via magnetic fields	Not superparamagnetic	Jeon et al., 2021; Zhao et al., 2020 43 49
Optical Properties	Can be engineered for fluorescence and photothermal effects	No optical properties	Zhao et al., 2020; Caravan et al., 1999 49 6

Versatility	Broad applications: MRI, drug delivery, and therapy	Primarily limited to MRI contrast	Gupta et al., 2005; Wahsner et al., 2018 36 44
Future Outlook	Rapidly advancing with promising new applications	Established technology with limited innovation	Jeon et al., 2021; Gulani et al., 2017 43 10

6. Future Directions: Dual-Mode Imaging and Theranostics

Development of dual-mode agents combining the positive contrast advantages of T_1 imaging with the negative contrast qualities of T_2 imaging is the next stage of study in MRI contrast agents. Researchers hope to produce agents with enhanced diagnostic accuracy in a single scan [13] [25] by customizing surface modifications that is, adding gadolinium ions onto IO-NPs).

Moreover, including therapeutic features into IONPs has a great potential in theragnostic. Real-time monitoring of treatment responses could be made possible by smart nanoparticles releasing medications in response to particular triggers (such as pH changes in tumor microenvironments). This might not only increase therapeutic efficacy but also enable stratification of patients into responders and non-responders, hence improving individualized medicine [10] [13]. To address present difficulties with nanoparticle aggregation, size variation, and inconsistent signal amplification, efforts are now under way to provide standardized synthesis and imaging methods. Broad clinical translation also depends on investigating scalable production technologies and environmentally friendly synthesis approaches.

7. Conclusion

Gadolinium-based contrast agents have historically been regarded as the gold standard in MRI owing to their superior T_1 contrast enhancement. Nonetheless, safety issues specifically gadolinium retention and the potential for NSF have prompted the investigation of alternatives. Iron oxide nanoparticles, due to their intrinsic biocompatibility, multifaceted imaging abilities, and potential for theranostics applications, present a promising alternative. Despite existing hurdles in enhancing their signal characteristics and standardizing manufacturing processes, continuous research is progressing their clinical use. The future of MRI contrast agents probably resides in the creation of multifunctional, dual-mode agents that combine diagnostic imaging with targeted therapy. Interdisciplinary collaboration and ongoing innovation in nanoparticle synthesis, surface engineering, and imaging protocol design position IONPs to transform diagnostic imaging and personalized medicine.

References

1-Hashemi RH, Bradley WG, Lisanti CJ. MRI: The Basics (4th ed.). Philadelphia: Lippincott Williams & Wilkins; 2017.

2- Al-Shimmery, H., & Raheem, A. (2022). Influence of Anxiety and Claustrophobia on Blood Pressure and Heart Rate during MRI Scan. *Medico-Legal Update*, *22*(3).

3- RAHEEM, A. M., H. A., & Abdul KAREEM, S. K. (2019). The incidence of ultrasound diagnosed uterine abnormalities related to miscarriage rates–a local audit. Romanian JouRnal of medical PRactice, 14(3), 67.

4- Bernstein, M. A., King, K. F., & Zhou, X. J. (2004). Handbook of MRI pulse sequences. Academic Press.

5- Elster, A. D. (2012). Questions and answers in magnetic resonance imaging (2nd ed.). Mosby.

6-Caravan, P., Ellison, J. J., McMurry, T. J., & Lauffer, R. B. (1999). Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications. Chemical Reviews, 99(9), 2293–2352.

7- Radhi, M. M., Al-Shimmari, H. A. T., Al-Mulla, E. A. J., Abdullah, A. A., &Wadday, A. G. (2017). New voltammetric study of MgCl2 as alternative contrast media in MRI molecular imaging. Nano Biomed. Eng, 9(2), 152-161

8- Dunya Ali Mustafa, Haydar Abdulkadeer Taheer Al-Shimmari, Muhammed Mizher Radhi, Use of MgCl2 Nanoparticles as Alternative Contrast Media in Magnatic Resonance Imaging Molecular Imaging and Analyzed by Voltammetric Technique, Nano Biomed. Eng., 2020, 12(2): 148- 152.

9- Weinmann, H. J., Ebert, W., Misselwitz, B., & Schmitt-Willich, H. (2003). Tissue-specific MR contrast agents. European Journal of Radiology, 46(1), 33–44.

10- Gulani, V., Calamante, F., Shellock, F. G., Kanal, E., & Reeder, S. B. (2017). Gadolinium deposition in the brain: Summary of evidence and recommendations. The Lancet Neurology, 16(7), 564–570. https://doi.org/10.1016/S1474-4422(17)30158-8

11- Kanda, T., Fukusato, T., & Matsuda, M. (2014). Gadolinium deposition in the brain: A review of current knowledge and future directions. Radiology, 270(3), 639-648. https://doi.org/10.1148/radiol.13132587.

12- Mahmoudi, M., Simchi, A., Imani, M., & Milani, A. S. (2011). Cytotoxicity evaluations of superparamagnetic iron oxide nanoparticles: Cell "vision" versus physicochemical properties. ACS Nano, 5(9), 7265-7278.

13- Arami, H., Khandhar, A., Liggitt, D., & Krishnan, K. M. (2015). In vivo delivery, pharmacokinetics, biodistribution, and toxicity of iron oxide nanoparticles. Chemical Society Reviews, 44(23), 8576-8607.

14- Ahmadpoor, F., Masood, A., Feliu, N., & Parak, W.J. (2021). The effect of surface coating of iron oxide nanoparticles on magnetic resonance imaging relaxivity. Frontiers in Chemistry.

15- Ajinkya, N., Yu, X., Kaithal, P., Luo, H., Somani, P., & Ramakrishna, S. (2020). Magnetic iron oxide nanoparticle (IONP) synthesis to applications: present and future. Materials, 13(20), 4644. https://doi.org/10.3390/ma13204644

16- Shubayev, V. I., Pisanic, T. R., & Jin, S. (2009). Magnetic nanoparticles for theragnostics. Advanced Drug Delivery Reviews, 61(6), 467-477.

17- Veiseh, O., Gunn, J. W., & Zhang, M. (2010). Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Advanced Drug Delivery Reviews, 62(3), 284-304.

18- Bulte, J. W., & Kraitchman, D. L. (2004). Iron oxide MR contrast agents for molecular and cellular imaging. NMR in Biomedicine, 17(7), 484-499.

19- Deoni, S. C. L., Peters, T. M., & Rutt, B. K. (2008). High-resolution T1 mapping of the brain at 3T with driven equilibrium single pulse observation of T1 (DESPOT1). Journal of Magnetic Resonance Imaging, 28(3), 631–640. https://doi.org/10.1002/jmri.21475

20-Weinmann, H. J., Brasch, R. C., Press, W. R., & Wesbey, G. E. (1984). Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent. American Journal of Roentgenology, 142(3), 619-624.

21.Gulani, V., Calamante, F., Shellock, F. G., Kanal, E., & Reeder, S. B. (2017). Gadolinium deposition in the brain: Summary of evidence and recommendations. The Lancet Neurology, 16(7), 564–570. https://doi.org/10.1016/S1474-4422(17)30158-8

22- Kobayashi, Y., Kanda, T., Ishii, K., Kawaguchi, H., & Kitajima, K. (2021). Comparison of human tissue gadolinium retention and elimination between gadoteridol and gadobenate dimeglumine. Radiology, 301(3), 636–645.

23- Rudnick, M. R., Wahba, I. M., Leonberg-Yoo, A. K., Miskulin, D., & Litt, H. I. (2021). Risks and options with gadolinium-based contrast agents in patients with CKD: a review. American Journal of Kidney Diseases, 77(4), 517-528.

24- Turyanskaya, A., Rauwolf, M., Pichler, V., Simon, R., Burghammer, M., Fox, O. J., ... & Streli, C. (2020). Detection and imaging of gadolinium accumulation in human bone tissue by micro-and submicro-XRF. Scientific reports, 10(1), 6301.

25- Vander Molen, A.J., Quattrocchi, C.C., Mallio, C.A. et al. Ten years of gadolinium retention and deposition: ESMRMB-GREC looks backward and forward. Eur Radiol 34, 600–611 (2024).
26- Daldrup-Link, H. E. (2017). Ten things you might not know about iron oxide nanoparticles. Radiology, 284(3), 616-629.

27- Aires, A., Fernández-Afonso, Y., Guedes, G., & others. (2022). Engineered protein-driven synthesis of tunable iron oxide nanoparticles as T1 and T2 magnetic resonance imaging contrast agents. Chemistry of Materials, 34(10), 4567–4578.

28- Yeh, Y. C., Creran, B., & Rotello, V. M. (2020). Gold nanoparticles: Preparation, properties, and applications in bionanotechnology. Nanoscale, 4(6), 1871-1880.

29- Albanese, A., Tang, P. S., & Chan, W. C. (2012). Annual Review of Biomedical Engineering, 14.
30- Singh, N., Jenkins, G. J., Asadi, R., & Doak, S. H. (2010). Potential toxicity of superparamagnetic iron oxide nanoparticles (SPIONs). Nano Reviews, 1(1), 5358.

31- Perlman, O., & Azhari, H. (2017). Ultrasonic computed tomography imaging of iron oxide nanoparticles. Physics in Medicine & Biology, 62(3), 825.
32- Athertya, J. S., Akers, J., Sedaghat, S., Wei, Z., & Zhang, X. (2023). Detection of iron oxide nanoparticle (IONP)-labeled stem cells using quantitative ultrashort echo time imaging: A feasibility study. Biomedical Imaging in Medicine, 15(2), 123-134.

33- Zhang, J., Chamberlain, R., Etheridge, M., Idiyatullin, D., Corum, C., Bischof, J., & Garwood, M. (2014). Quantifying iron-oxide nanoparticles at high concentration based on longitudinal

relaxation using a three-dimensional SWIFT look-locker sequence. Magnetic resonance in medicine, 71(6), 1982-1988.

34- Ichkitidze, L. P., Filippova, O. V., Belodedov, M. V., Galechyan, G. Y., Savelyev, M. S., Gerasimenko, A. Y., ... & Selishchev, S. V. (2023, October). Behavior of Magnetic Nanoparticles in the Phantom of the Biological Medium. In International Conference on Physics and Mechanics of New Materials and Their Applications (pp. 549-562). Cham: Springer Nature Switzerland.

35-Sun, Z., Worden, M., Thliveris, J. A., Hombach-Klonisch, S., Klonisch, T., van Lierop, J., ... & Miller, D. W. (2016). Biodistribution of negatively charged iron oxide nanoparticles (IONPs) in mice and enhanced brain delivery using lysophosphatidic acid (LPA). Nanomedicine: Nanotechnology, Biology and Medicine, 12(7), 1775-1784.

36- Gupta, A., Shin, J. H., Lee, M. S., Park, J. Y., Kim, K., Kim, J. H., ... & Lee, J. S. (2019). Voxel-based dosimetry of iron oxide nanoparticle-conjugated 177Lu-labeled folic acid using SPECT/CT imaging of mice. Molecular Pharmaceutics, 16(4), 1498-1506.

37-Bashir, M. R., Bhatti, L., Marin, D., & Nelson, R. C. (2015). Emerging applications for ferumoxytol as a contrast agent in MRI. Journal of Magnetic Resonance Imaging, 41(4), 884-898.

38- Aram, H., Wang, L., Yu, Q., Qian, W., Tiwari, D., Yi, H., ... & Mao, H. (2022). Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer. International journal of nanomedicine, 3781-3794.

39- Huang, Y., Hsu, J. C., Koo, H., & Cormode, D. P. (2022). Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle. Theranostics, 12(2), 796–816.

40- Barcikowski, S., & Gökce, B. (2018). Laser synthesis and processing of colloids: Fundamentals and applications. Chemical Reviews, 118(12), 11972–12002. https://doi.org/10.1021/acs.chemrev.8b00177

41- Al-Shimmari, H. A. T., Suzana, A. H., Suppiah, S., Radhi, M. M., Kadhim, D. A., Abid, M. A., & Abdulkadeer, H. A. (2023). Electrochemical safety assessment of magnetite nanoparticles: Utilizing cyclic voltammetry for alternative biogenic MRI contrast media. International Journal of Medical Toxicology & Forensic Medicine, 27(5). https://doi.org/10.47059/ijmtlm/V27I5/001

42- Schieda, N., Blaichman, J. I., Costa, A. F., Glikstein, R., Hurrell, C., James, M., ... & van der Pol, C. B. (2018). Gadolinium-based contrast agents in kidney disease: A comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Canadian Association of Radiologists Journal, 69(2), 136–150. https://doi.org/10.1016/j.carj.2017.11.002

43- Jeon, M., Halbert, M. V., Stephen, Z. R., & Zhang, M. (2021). Iron oxide nanoparticles as T1 contrast agents for magnetic resonance imaging: fundamentals, challenges, applications, and prospectives. Advanced Materials, 33(23), 1906539. https://doi.org/10.1002/adma.201906539

44 Wahsner, J., Gale, E. M., Rodríguez-Rodríguez, A., & Caravan, P. (2018). Chemistry of MRI contrast agents: current challenges and new frontiers. Chemical Reviews.

45- Runge, V. M. (2017). Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus. Investigative Radiology, 52(6), 317-323.

46- Farinha, P., Coelho, J. M., Reis, C. P., & Gaspar, M. M. (2021). A comprehensive updated review on magnetic nanoparticles in diagnostics. Nanomaterials, 11(12), 3432. https://doi.org/10.3390/nano11123432.

47- Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008). Magnetic iron oxide nanoparticles: Synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chemical Reviews, 108(6), 2064–2110.

48- Radbruch, A., Weberling, L. D., Kieslich, P. J., Eidel, O., Burth, S., Kickingereder, P., ... & Schlemmer, H. P. (2015). Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology, 275(3), 783–791. https://doi.org/10.1148/radiol.2015150337

49- Zhao, S., Yu, X., Qian, Y., Chen, W., & Shen, J. (2020). Multifunctional magnetic iron oxide nanoparticles: An advanced platform for cancer theranostics. Theranostics, 10(14), 6278–6309.

50- Montiel Schneider, M. G., Martín, M. J., Otarola, J., Vakarelska, E., Simeonov, V., Lassalle, V., & Nedyalkova, M. (2022). Biomedical applications of iron oxide nanoparticles: Current insights, progress and perspectives. Pharmaceutics, 14(1), 204. https://doi.org/10.3390/pharmaceutics14010204